Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Study sponsor: Revolution Medicines, Inc. · RVMD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-05-10Estimated
Enrollment · participants500Estimated
Source updated2026-10-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.